Updates in non-small cell lung cancer - insights from the 2009 45th annual meeting of the American Society of Clinical Oncology

Table 5 PFS and OS in Zodiac, Zeal, and Zest studies.

TRIAL	Zodiac		Zeal		Zest
Treatment	Vandetanib+Docetaxel	Placebo+Docetaxel	Vandetanib+Pemetrexed	Placebo+Pemetrexed	Vandetanib	Erlotinib
Median PFS	4.0 Months	3.2 Months	17.6 Weeks	11.9 Weeks	11.3 Weeks	8.9 Weeks
HR	0.79	0.91	0.86	0.86	0.98	1.01
P-Value	< 0.001	0.196	0.108	0.22	0.72	0.83
Median OS Months	10.6	10.0	10.5	9.2	6.9	7.8

ISSN: 1756-8722